| Excerpt | Relevance | Reference |
|---|
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and constitutes a major risk factor for progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC)." | 5.56 | Hypericin attenuates nonalcoholic fatty liver disease and abnormal lipid metabolism via the PKA-mediated AMPK signaling pathway in vitro and in vivo. ( Bai, M; Bao, Y; Huang, Y; Li, Y; Liang, C; Liu, L; Song, Z; Sun, L; Wang, S; Yang, H; Yi, J; Yu, C, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and constitutes a major risk factor for progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC)." | 1.56 | Hypericin attenuates nonalcoholic fatty liver disease and abnormal lipid metabolism via the PKA-mediated AMPK signaling pathway in vitro and in vivo. ( Bai, M; Bao, Y; Huang, Y; Li, Y; Liang, C; Liu, L; Song, Z; Sun, L; Wang, S; Yang, H; Yi, J; Yu, C, 2020) |